Moderate to Severe Rheumatoid Arthritis: When Methotrexate Is Not Enough and What the Next Step Involves
The phrase moderate to severe is not a description of how bad the days feel. It is a measured category, and the measurement decides whether treatment gets escalated, which drug comes next, and in some countries whether it is funded at all.
This page is about the part of rheumatoid arthritis that starts where conventional treatment stops working. The basics of diagnosis and the early disease are covered in our guides to rheumatoid arthritis causes, symptoms and treatment and how rheumatoid arthritis is diagnosed.
📏 What moderate to severe actually means
Disease activity is scored. Two scores are used most, and both combine tender and swollen joint counts with the patient own global assessment, with or without a blood marker of inflammation.
| Activity level | DAS28 | CDAI | What it means for treatment |
|---|---|---|---|
| Remission | Below 2.6 | 2.8 or less | The target. Continue and consider careful reduction later |
| Low | 3.2 or less | Above 2.8 to 10 | Acceptable alternative target, particularly in long-standing disease |
| Moderate | Above 3.2 to 5.1 | Above 10 to 22 | Not good enough. Treatment should be changed rather than continued |
| High | Above 5.1 | Above 22 | Escalation, and usually quickly |
💡 Two things follow from this that change how appointments should go.
First, ask for your score. If treatment decisions are being made on a conversation about how you have been feeling rather than on a joint count and a number, the decisions are being made on weaker evidence than they need to be.
Second, pain and disease activity are different things. Joints can be quietly eroding while the pain is tolerable, and pain can be severe from damage already done while the inflammation is controlled. The treatment follows the inflammation.
🎯 Treat to target, with the actual timetable
The principle is stated everywhere and the timings are what make it work. Drifting along in moderate activity for a year because nothing is dramatically wrong is the commonest way joints get lost.
- 🎯 Agree a target — remission, or low disease activity where remission is unrealistic
- 📅 Measure every one to three months while the disease is active
- 🔄 At 3 months: if there has been no meaningful improvement, change the treatment. Not wait. Not increase the painkiller
- 🚩 At 6 months: if the target has not been reached, change the treatment
- 📉 Once the target has been held for six months or more, careful reduction can be discussed — usually tapering the steroid first, then spacing or reducing the advanced drug, with the conventional DMARD kept longest
Behind the urgency is the window of opportunity: inflammation controlled in the first months of disease produces better long-term joint and function outcomes than the same control achieved two years later. Erosions do not reverse. What is prevented stays prevented and what is lost stays lost, which is why the timetable above is a timetable rather than a suggestion.
💊 The conventional sequence, and where it actually sits
Nobody goes to an advanced drug first. The sequence matters because escalation past it is only justified once it has genuinely been tried.
| Medicine | Role and dosing |
|---|---|
| Methotrexate | The anchor drug of rheumatoid arthritis. 7.5 to 15 mg ONCE WEEKLY, increased to 20 to 25 mg weekly as needed, with folic acid 5 mg once weekly on a different day. Also the backbone that advanced drugs are added to, since combinations work better than either alone |
|
Arava (Leflunomide) generic: Lefuheal |
10 to 20 mg daily. Comparable in effect to methotrexate and the usual alternative where methotrexate cannot be used. Very long half-life, which matters for the pregnancy section below |
| Azulfidine (Sulfasalazine) | Built up to 2 to 3 g daily in divided doses. Often used in combination, and the safest conventional option in pregnancy |
| Hydroxychloroquine | The mildest conventional DMARD, used mainly in triple combination. Needs eye monitoring. Not currently stocked here |
| Imuran (Azathioprine) | An older option, now used mainly where the others are unsuitable or where another autoimmune condition coexists |
| Prednisolone | Bridging only. Fast and effective, and the plan should always include coming off it. Long-term low-dose steroid causes bone loss, diabetes, cataract and infection, and the total exposure is what harms |
| Arcoxia (Etoricoxib) | Symptom relief only. Does nothing to the disease and does not prevent erosions. Feeling better on an anti-inflammatory is not disease control |
🚨 Methotrexate is taken once a week, not once a day. Daily dosing by mistake is a recognised cause of death from this drug. One day of the week, written down, ideally the same day each week, with the folic acid on a different day. If a dose is missed, it is not doubled.
Alcohol in any quantity beyond modest increases liver risk alongside it, and blood tests — full blood count, liver function and kidney function — are checked every two to four weeks at first and then roughly every three months for as long as it is taken.
⬆️ When escalation is justified, and to what
The threshold is: failure of at least one conventional DMARD at an adequate dose for an adequate time, usually methotrexate, with disease activity still moderate or high. Two broad options exist beyond that.
Biologics — injected or infused antibodies against specific targets, most commonly TNF. JAK inhibitors — tablets, including baricitinib, which block signalling inside the cell rather than a molecule outside it.
The sequencing between them is not a matter of preference any more. Following the safety reviews described below, regulators in the United States and Europe now place JAK inhibitors after a TNF inhibitor rather than alongside one, except where a biologic cannot be used. That is a meaningful change from how these drugs were positioned when they launched, and a lot of material written about them predates it.
📈 Baricitinib: the dosing
Olumiant (Baricitinib) is a selective JAK1 and JAK2 inhibitor taken as a tablet, with or without methotrexate, in adults with moderate to severe rheumatoid arthritis who have not responded adequately to one or more DMARDs.
- 🔹 4 mg once daily is the usual dose, at any time, with or without food
- 🔸 2 mg once daily is used instead in people aged 75 or over, those with a history of chronic or recurrent infection, and where kidney function is reduced with an eGFR between 30 and 60
- 🚫 Not recommended at all if eGFR is below 30, or in moderate to severe liver impairment
- 📉 Reduction from 4 mg to 2 mg is appropriate once sustained control has been achieved, and is worth asking about rather than staying on the higher dose indefinitely
- ⏳ Response is usually visible within one to two weeks, which is faster than conventional DMARDs. Reassessment at three months decides whether it continues
- 💊 Dose halved if taken with a strong inhibitor of the OAT3 transporter, such as probenecid
🚨 The JAK inhibitor safety picture, in full
This is the part that has to be read before the decision rather than after it. The class carries a boxed warning, and it is not a formality.
⚠️ What the warnings cover.
Serious infections. Bacterial, fungal, viral and opportunistic, including tuberculosis — both new and reactivated from a latent infection — and shingles, which is notably more common on this class.
Mortality. A large randomised safety trial of another drug in this class, in people aged 50 and over with a cardiovascular risk factor, found higher all-cause death than with a TNF inhibitor. The finding was extended across the class.
Cancer. Higher rates of malignancy including lymphoma and lung cancer, with the excess concentrated in current and former smokers.
Heart attack and stroke. Higher rates of major cardiovascular events, again concentrated in those with existing cardiovascular risk.
Blood clots. Deep vein thrombosis, pulmonary embolism and arterial thrombosis. This one is particularly associated with baricitinib and is dose-related.
Who should generally not take it: age 65 or over, current or past smoking of any significant amount, existing cardiovascular disease or multiple risk factors for it, a history of blood clots or a known clotting tendency, and a history of malignancy — unless no suitable alternative exists and the decision is made deliberately with a specialist.
None of that means the drug should not be used. It means it is a specialist decision with a documented conversation, it is the wrong choice for a predictable group of people, and it is not something to start on the basis of an article — including this one.
🧪 Before it is started
- 🫁 Tuberculosis screening, and treatment of latent infection first if found
- 🟡 Hepatitis B and C testing, since both can reactivate
- 🩸 Full blood count — it is not started if lymphocytes are below 0.5, neutrophils below 1.0, or haemoglobin below 8 g/dL
- 🧫 Liver function, kidney function and a lipid profile
- 💉 Vaccination brought up to date, including shingles, pneumococcal and influenza, before starting — live vaccines cannot be given once immunosuppressed
- 🤰 Pregnancy excluded, and contraception discussed
📅 While it is being taken
Blood count, liver function and lipids at roughly 4 and 12 weeks, then about every three months. Lipids rise on this class and often need treating. Any new cough, fever, weight loss or night sweats is investigated for tuberculosis rather than assumed to be a cold.
🌡️ The infection rule, which matters more than anything else day to day.
Any fever or suspected infection means stopping the drug temporarily and seeking advice the same day. Not finishing the week and mentioning it at the next appointment. Immunosuppression blunts the usual signs, so an infection can be well advanced while looking mild, and the inflammatory markers that would normally rise may stay misleadingly low.
Specific things to report immediately: a painful blistering rash in a band on one side of the body, which is shingles and needs treating within 72 hours; shortness of breath or a swollen painful calf, which could be a clot; and any new chest pain.
🤰 Pregnancy and conception
This gets left out of articles about advanced treatment and it is one of the most consequential sections for anyone of reproductive age.
- 🚫 Methotrexate is teratogenic and is stopped before conception — usually at least three months beforehand, and the guidance applies to prospective fathers as well as mothers in many protocols
- 🚫 Leflunomide is teratogenic with a very long half-life. Without an active washout procedure, it can take up to two years to clear sufficiently. If pregnancy is a possibility at any point, this needs planning years ahead rather than months
- 🚫 Baricitinib is contraindicated in pregnancy and effective contraception is required during treatment and for a period afterwards
- ✅ Sulfasalazine, hydroxychloroquine and certain biologics are the options generally considered compatible, which is why the plan changes well before conception rather than at a positive test
- 💬 Raise it early. Any woman of reproductive age starting any of these drugs should have had this conversation, and a great many have not
❤️ The parts of the disease that are not joints
Rheumatoid arthritis shortens life mainly through things that happen outside the joints, and the screening for them is routinely missed.
| Risk | What to do about it |
|---|---|
| Cardiovascular disease | Rheumatoid arthritis roughly doubles the risk, through the inflammation itself as much as through conventional factors. Blood pressure, cholesterol, glucose and smoking all need active attention, and risk calculators tend to underestimate it here — a multiplier is applied. Controlling the disease is itself cardiovascular prevention |
| Osteoporosis | From the inflammation, from reduced activity and from steroids. Bone density assessment, vitamin D and calcium, and a bone-protecting drug where steroids are being used for any length of time |
| Lung disease | Interstitial lung disease occurs in a meaningful minority and is commoner in smokers and in those with high antibody levels. Persistent dry cough or breathlessness on exertion needs investigating, not attributing to being unfit or to the arthritis limiting exercise |
| Infection | Raised by the disease and by every drug used to treat it. Annual influenza, pneumococcal and shingles vaccination, ideally arranged before immunosuppression starts |
| Lymphoma | Modestly increased, and the increase tracks sustained high disease activity more than it tracks the medication — which is an argument for controlling the disease rather than tolerating it |
| Depression and fatigue | Common, under-treated, and strongly affecting whether treatment gets taken at all. Fatigue frequently persists after joints are controlled and deserves addressing in its own right |
Alongside those: stopping smoking does more here than in almost any other condition, because it worsens the disease, reduces how well methotrexate and biologics work, drives the lung complications, and is the single biggest amplifier of the JAK inhibitor cancer and cardiovascular risks above. Exercise, including resistance training, is safe in controlled disease and protects muscle and bone. Neither replaces the drugs and both change the outcome.
The conventional and advanced options stocked here sit in the arthritis category, and early-disease management is covered in our guide to stopping rheumatoid arthritis before it spreads.
📞 When to seek help
Same day, and stop the drug:
- Fever, or any suspected infection, on methotrexate, leflunomide, azathioprine or baricitinib
- A painful blistering rash in a band on one side of the body — shingles, treatable within 72 hours
- Breathlessness, chest pain, or a swollen painful calf — possible clot or cardiac event
- Mouth ulcers, unexplained bruising or bleeding, or a sore throat with fever on methotrexate — possible marrow suppression
- Yellow skin or eyes, dark urine, or right-sided abdominal pain
Promptly:
- A new persistent dry cough or breathlessness on exertion — needs investigating for lung involvement
- Unexplained weight loss, drenching night sweats or persistent cough — assessed for tuberculosis rather than assumed
- Disease activity still moderate or high at three months on a treatment — ask for the plan to be changed rather than extended
- Never having been told your disease activity score
- Pregnancy being considered at any point, on any of these drugs
- Blood monitoring not arranged, or appointments drifting while symptoms continue
- Still on prednisolone months after it was meant to be a bridge
- Age over 65, smoking history, previous clot or previous cancer and a JAK inhibitor being proposed — ask specifically how the class warnings apply to you
❓ Frequently asked questions
What counts as moderate to severe rheumatoid arthritis?
It is scored rather than described. A DAS28 above 3.2, or a CDAI above 10, is moderate; above 5.1 and above 22 respectively are high. Moderate activity is not a reason to continue the same treatment — it is a reason to change it.
What is the baricitinib dose?
4 mg once daily, with or without food. 2 mg once daily instead in people aged 75 or over, those with a history of chronic or recurrent infection, and where eGFR is 30 to 60. It is not recommended below an eGFR of 30.
Who should not take a JAK inhibitor?
Generally people aged 65 or over, current or former smokers, those with cardiovascular disease or several risk factors, anyone with a history of blood clots or a clotting tendency, and anyone with a history of cancer — unless no suitable alternative exists.
What tests are needed before starting baricitinib?
Tuberculosis screening, hepatitis B and C testing, full blood count, liver and kidney function, a lipid profile, pregnancy exclusion, and vaccinations brought up to date beforehand since live vaccines cannot be given once immunosuppressed.
How often is methotrexate taken?
Once a week, never daily — daily dosing in error is a recognised cause of death. Typically 7.5 to 15 mg weekly rising to 20 to 25 mg, with folic acid 5 mg once weekly on a different day, and regular blood monitoring.
My joints feel better on an anti-inflammatory. Is that enough?
No. Anti-inflammatories relieve symptoms and do nothing to the disease or to erosion. Joints can be eroding while the pain is tolerable, which is why treatment follows the measured inflammation rather than how the days feel.
How long before treatment should be changed if it is not working?
If there has been no meaningful improvement at three months, or the target has not been reached at six, the treatment is changed. Disease activity is measured every one to three months while it remains active.
What should I do if I get a fever while on these drugs?
Stop the drug temporarily and seek advice the same day. Immunosuppression blunts the usual signs, so an infection can be well advanced while appearing mild, and the blood markers that would normally rise may stay misleadingly low.
Can I take these medicines if I want to get pregnant?
Methotrexate, leflunomide and baricitinib are all unsuitable. Leflunomide in particular has a very long half-life and can take up to two years to clear without an active washout, so this needs planning years rather than months in advance.
Why does smoking matter so much in rheumatoid arthritis?
It worsens the disease, reduces how well methotrexate and biologics work, drives the lung complications, and is the largest amplifier of the cancer and cardiovascular risks carried by JAK inhibitors. Few conditions reward stopping as much.
📑 Sources and editorial
- ACR and EULAR recommendations for the management of rheumatoid arthritis, including treat-to-target principles and the sequencing of conventional, biological and targeted synthetic DMARDs
- Validation and interpretation of the DAS28 and CDAI disease activity measures and their cut-points
- Prescribing information for baricitinib, including dosing by age and renal function, pre-treatment screening and the boxed warning
- FDA and EMA safety reviews of Janus kinase inhibitors covering mortality, malignancy, major adverse cardiovascular events and thrombosis, and the resulting restrictions on use
- The randomised safety surveillance trial comparing a JAK inhibitor with TNF inhibitors in patients aged 50 and over with a cardiovascular risk factor
- Prescribing information for methotrexate, leflunomide, sulfasalazine and azathioprine, including monitoring schedules and teratogenicity
- Guidance on antirheumatic drugs before and during pregnancy and breastfeeding, including leflunomide washout
- EULAR guidance on cardiovascular risk management in inflammatory joint disease, and evidence on interstitial lung disease and osteoporosis in rheumatoid arthritis
- Studies of smoking on disease severity, treatment response and extra-articular complications
- Related reading: rheumatoid arthritis causes, symptoms and treatment, stopping rheumatoid arthritis early, how rheumatoid arthritis is diagnosed
- Related products: Olumiant (Baricitinib), Methotrexate, Arava (Leflunomide), Azulfidine (Sulfasalazine), arthritis category
- RXshop Editorial Team — reviewed by Emily Chen, MD, MPH — Internal Medicine Specialist
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.